中国经济网北京4月2日讯睿智医药（300149）(300149.SZ)昨晚发布2024年度向特定对象发行股票预案 (修订稿)。本次向特定对象发行股票预计募集资金总额不超过31,630.38万元(含本数)，扣除发行费用后 的募集资金净额将全部用于补充流动资金、偿还银行借款。 本次向特定对象发行股票的发行对象为睿联投资，发行对象已与公司签署了《附条件生效的股份认购协 议(修订稿)》，拟以现金方式认购本次发行的股票。截至预案公告时，睿联投资的实际控制人WOO SWEE LIAN为上市公司董事长、首席执行官(CEO)，其合计控制上市公司5%以上股份，且WOOSWEE LIAN在完成广东省江门市中级人民法院出具的第(2024)粤07民初66号《民事调解书》强制执行过户 后，将成为公司的控股股东和实际控制人；本次发行后睿联投资将成为公司的控股股东，WOO SWEE LIAN仍为公司实际控制人。根据《上市规则》的规定，本次向特定对象发行股份构成关联交易。 本次向特定对象发行股票的定价基准日为公司第六届董事会第五次会议决议公告日。本次向特定对象发 行股票的发行价格为5.27元/股，不低于定价基准日前20个交易日公司股票交易均 ...

睿智医药科技股份有限公司（以下简称"公司"）拟向特定对象发行股票， 募集资金不超过 31,630.38 万元（以下简称"本次发行"）。根据《国务院办公厅 关于进一步加强资本市场中小投资者合法权益保护工作的意见》（国办发 2013110 号）《国务院关于加强监管防范风险推动资本市场高质量发展的若干意 见》（国发202410 号）和《关于首发及再融资、重大资产重组摊薄即期回报有 关事项的指导意见》（证监会公告201531 号）等法律、法规、规章及规范性文 件的要求，为维护中小投资者利益，公司就本次发行对即期回报摊薄的影响进行 了认真、审慎、客观的分析，并提出了具体的填补回报措施，且相关主体对公司 填补回报措施能够得到切实履行做出了承诺。具体情况如下： 证券代码：300149 证券简称：睿智医药 公告编号：2025-15 睿智医药科技股份有限公司 关于 2024 年度向特定对象发行股票摊薄即期回报的影响与填补回报 措施及相关主体承诺（修订稿）的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次发行摊薄即期回报对公司主要财务指标的影响 （一）本次发行摊薄即期回报 ...

Group 1 - The core viewpoint of the article is that Ruizhi Pharmaceutical is planning a private placement of shares to enhance its capital strength and seize opportunities in the CRO/CDMO industry, which is expected to continue growing due to increasing demand for drug development and production services [1][6][19] Group 2 - The background of the issuance is that the company operates in the CRO/CDMO industry, providing drug discovery, development, and production services to global pharmaceutical companies and research institutions [1][2] - The demand for CRO/CDMO services remains strong due to the increasing focus on innovative drug development and the need for cost-effective solutions in the pharmaceutical industry [2][3] - The industry is characterized by a continuous need for outsourcing drug research and production, driven by advancements in technology and the emergence of new drug targets [2][3][4] Group 3 - The company aims to raise up to 316.30 million RMB through this issuance, which will be used to supplement working capital and repay bank loans, thereby optimizing its financial structure and enhancing its competitive edge [6][19] - The issuance will involve the issuance of domestic ordinary shares (A shares) at a price of 5.27 RMB per share, which is not lower than 80% of the average trading price over the previous 20 trading days [8][9] Group 4 - The issuance is deemed necessary and reasonable as it aligns with the company's strategic goals and will enhance its ability to respond to market opportunities [19][24] - The company has committed to measures to mitigate the potential dilution of immediate returns for shareholders resulting from the issuance [19][20][23]

Core Viewpoint - The agreement outlines the terms for the issuance of shares by Ruizhi Medical Technology Co., Ltd. to Jiangmen Ruilian Medical Investment Co., Ltd. for the year 2024, including share transfer and ownership changes [1][2][3]. Group 1: Share Issuance Agreement - The agreement was signed on April 1, 2025, between Ruizhi Medical Technology Co., Ltd. and Jiangmen Ruilian Medical Investment Co., Ltd. [1] - The total registered capital of Ruizhi Medical is RMB 497.96 million, with a total share count of 100% held by MEDICAL LIMITED [1]. - WOO SWEE LIAN, the actual controller, currently holds 5.11% of the shares, with an additional 4.56% held by MEGA STAR [1]. Group 2: Share Transfer and Ownership Changes - Following a court ruling, WOO SWEE LIAN and his associates will hold 15.70% of the shares after the forced transfer of 30,033,098 shares from another shareholder [2]. - After the completion of a share transfer agreement, WOO SWEE LIAN and his associates will collectively own 21.18% of the shares, maintaining his position as the controlling shareholder [3]. Group 3: Subscription Details - The agreement allows for the issuance of up to 60,019,704 shares, representing 30% of the total share capital prior to the issuance, at a price of RMB 5.27 per share [4][5]. - The subscription amount will be determined by the number of shares multiplied by the issuance price, with funds sourced legally by the subscriber [5]. - The shares subscribed will have a lock-up period of 18 months post-issuance [5]. Group 4: Legal and Compliance - The agreement is subject to approval from the board of directors and shareholders, as well as regulatory approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [7]. - Any modifications to the agreement must be documented in writing and comply with legal procedures [7][8].

Financial Performance - The company reported a significant loss primarily due to a large goodwill impairment and an increase in period expenses[4]. - The company's revenue for 2021 was CNY 1,690,677,943.33, representing a 14.11% increase compared to CNY 1,481,591,872.64 in 2020[22]. - The net profit attributable to shareholders for 2021 was a loss of CNY 402,245,074.78, a decrease of 360.27% from a profit of CNY 154,550,403.78 in 2020[22]. - The net cash flow from operating activities for 2021 was CNY 378,219,891.25, which is a 10.22% increase from CNY 343,160,357.56 in 2020[22]. - The total assets at the end of 2021 were CNY 4,217,591,526.68, a 2.33% increase from CNY 4,121,581,017.24 at the end of 2020[22]. - The net assets attributable to shareholders decreased by 19.09% to CNY 1,964,444,590.44 at the end of 2021 from CNY 2,427,903,737.42 at the end of 2020[22]. - The basic earnings per share for 2021 was -CNY 0.81, compared to CNY 0.31 in 2020, reflecting a decline of 361.29%[22]. - The company reported a net loss attributable to shareholders of -40,224.51 million CNY, with a significant goodwill impairment of 36,760 million CNY impacting profitability[45]. Business Strategy and Focus - The company plans to focus on its core business to enhance its industry position, competitive capabilities, and sustainable development[4]. - The company plans to divest its prebiotic business to focus on CRO/CDMO services, with the sale of Quantum Gaoke (Guangdong) Bio Co., Ltd. approved by shareholders[35]. - The company aims to enhance its integrated pharmaceutical R&D service capabilities to foster long-term strategic partnerships with clients[67]. - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by the strategic appointments in its leadership team[145]. - The company is actively pursuing opportunities for mergers and acquisitions to bolster its market position and expand its product portfolio[147]. Risks and Challenges - The company faces various risks, including a decline in service demand, loss of core technology and management personnel, and risks related to new technology development failures[5]. - The audit report from Ernst & Young Huaming indicates a going concern uncertainty, highlighting the need for careful investor consideration[4]. - The company acknowledges the risk of goodwill impairment from its acquisition of Shanghai Ruizhi, emphasizing the need for effective resource integration to mitigate this risk[117]. - The company faces risks related to declining demand for pharmaceutical R&D services, which could significantly impact its business if industry growth slows[112]. - Natural disasters and public health emergencies, such as COVID-19, pose risks to the company's operations, particularly in facilities located in China, the US, and Denmark[123]. Governance and Management - The company has a clear governance structure that aligns with regulatory standards, with no significant discrepancies noted[137]. - The company has appointed a dedicated board secretary to manage investor relations and ensure effective communication with shareholders[135]. - The company has established a performance evaluation and incentive mechanism to link executive compensation with company performance, enhancing operational efficiency and management standards[134]. - The company reported a significant leadership change with the election of Zeng Xianwei as Chairman on November 18, 2021, and the appointment of Hua Fengmao as CEO on July 8, 2021[143]. - The company has undergone significant restructuring in its management team, which may lead to new strategic initiatives and operational efficiencies[148]. Research and Development - The company has developed a database of 8 million small molecules for virtual screening, enhancing its drug design capabilities[39]. - The company has established a comprehensive end-to-end service capability for biopharmaceuticals, covering early discovery to large-scale production[60]. - The company has established several research platforms, including an antibody-drug conjugate (ADC) R&D service platform and a large-scale recombinant monoclonal antibody R&D platform[193][196]. - The company is committed to enhancing its research and development capabilities, as evidenced by the appointment of experienced professionals in key positions[147]. Environmental Management - The company emphasizes environmental management, adhering to the Environmental Protection Law of the People's Republic of China, and aims to maximize resource efficiency while minimizing environmental impact[200]. - The company has established hazardous waste storage facilities with protective measures for the collection of hazardous waste generated[186]. - The company has implemented an environmental monitoring scheme, including annual monitoring of waste gas and quarterly monitoring of wastewater and noise, with third-party verification conducted[198]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[200]. Shareholder Relations and Dividends - No cash dividends, stock bonuses, or capital increases from reserves will be distributed to shareholders[6]. - The company reported a total cash dividend amount of ¥20,443,281.30 through share repurchase, with no cash dividends or stock bonuses distributed to shareholders for the fiscal year 2021[173]. - The company incurred losses in 2021 and decided not to distribute profits to ensure sufficient funding for long-term development[174]. - The company has a clear cash dividend policy that aligns with its articles of association and shareholder resolutions[172].

为保证公司经营决策顺利及董事会正常运作，经公司董事会全体董事推举， 由公司董事樊世新先生代行董事长、法定代表人职责，任期自公司第五届董事会 第三十四次会议审议通过之日起至董事会选举产生新任董事长之日止。公司将按 照法定程序，尽快完成新任董事长的选举和调整董事会专门委员会委员等相关工 作。 曾宪维先生在担任公司董事长期间恪尽职守、勤勉尽职，忠实地履行了各项 职责。公司董事会对曾宪维先生在任职期间为公司所做的贡献表示感谢！ 证券代码：300149 证券简称：睿智医药 公告编号：2023-55 睿智医药科技股份有限公司 关于董事长辞职暨推举董事代行董事长职责的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）董事会于近日收到公司董事 长曾宪维先生的书面辞职报告，曾宪维先生因个人原因，申请辞去公司董事、董 事长、董事会战略委员会、董事会薪酬与考核委员会主任委员的职务，曾宪维先 生辞职后将不再担任公司任何职务。曾宪维先生作为董事长的原定任期至公司第 五届董事会任期届满之日止。 截至本公告日，曾宪维先生未持有公司股份，亦不存在应当 ...

本议案以 6 票同意，0 票反对，0 票弃权获得通过。 特此公告。 睿智医药科技股份有限公司 睿智医药科技股份有限公司 第五届董事会第三十四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第五届董事会第三十四次 会议于 2023 年 11 月 27 日以书面、电话或电子邮件方式发出会议通知，并于 2023 年 12 月 1 日以通讯方式召开。本次会议应到董事 6 人，实到 6 人，本次会议由公 司董事樊世新先生主持，公司监事、高级管理人员列席了会议。本次会议召集与 召开符合有关法律、行政法规、部门规章和《公司章程》的有关规定。与会董事 经认真审议，形成决议如下： 1、审议通过了《关于推举董事代行董事长职责的议案》 鉴于曾宪维先生已辞去公司董事长的职务，为保证公司经营决策顺利及董事 会正常运作，经公司董事会全体董事推举，由公司董事樊世新先生代行董事长、 法定代表人职责，任期自本次董事会审议通过之日起至董事会选举产生新任董事 长之日止。 证券代码：300149 证券简称：睿智医药 公告编号：2023-54 董事 ...

关于睿智医药科技股份有限公司 2023 年第二次临时股东大会的 法律意见书 国枫律股字[2023]B0035 号 致：睿智医药科技股份有限公司（贵公司） 北京国枫（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2023 年第二次临时股东大会（以下简称"本次会议"）。 网址：www.grandwaylaw.com 上海市黄浦区中山东二路 600 号 BFC 外滩金融中心 S2 栋 23 层 23/F S2 Building, The Bund Finance Center, No. 600, Zhongshan No. 2, Road(E), Huangpu District, Shanghai, 200010, China 电话：86 21 2312 2000 传真：86 21 2312 2100 邮编：200010 北京 上海 深圳 成都 西安 杭州 香港 北京国枫（上海）律师事务所 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）、《上市公司股东大会规则》（以下简称《股东大 会规则》）、《律师事务所从事证券法律 ...

证券代码：300149 证券简称：睿智医药 公告编号：2023-53 睿智医药科技股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会无变更提案的情况。 一、会议召开和出席情况 1、召开方式：本次会议采取现场投票与网络投票相结合的方式。 2、现场会议地点：上海市浦东新区张江高科技园区金科路 2829 号金科中心 A 栋 上海睿智化学研究有限公司 3、现场会议召开时间：2023 年 11 月 29 日下午 14:30 4、网络投票时间：2023 年 11 月 29 日。其中，通过深圳证券交易系统进行网络 投票的具体时间为 2023 年 11 月 29 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票的具体时间为 2023 年 11 月 29 日上午 9:15 至下午 15:00 期间的任意时间。 5、召集人：公司董事会 6、出席现场会议和参加网络投票的股东及股东代表共 20 人（其中 2 名 ...

证券代码：300149 证券简称：睿智医药 公告编号：2023-49 睿智医药科技股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2023 年 10 月 24 日召开 第五届董事会第三十三次会议和第五届监事会第二十二次会议，审议通过了《关 于续聘会计师事务所的议案》，同意聘请安永华明会计师事务所（特殊普通合伙） （以下简称"安永华明"）为公司 2023 年度审计机构，聘任期为一年。本事项尚 需提交公司股东大会审议通过，2023 年度审计费用由董事会提请股东大会授权 公司管理层根据具体审计要求和审计范围与安永华明协商确定。具体情况如下： 一、拟聘任会计师事务所的基本信息 （一）机构信息 1、基本信息 安永华明会计师事务所（特殊普通合伙）于 1992 年 9 月成立，2012 年 8 月 完成本土化转制，从一家中外合作的有限责任制事务所转制为特殊普通合伙制事 务所。安永华明总部设在北京，注册地址为北京市东城区东长安街 1 号东方广场 安永大楼 17 层 01-12 室。 2、人员信 ...